This is a competitive renewal application for a project whose overall theme is the relationship between integrins, TGFbeta inhibitory response and malignant progression. Hypotheses for the previous period of support for this project were that integrin/ECM interactions modulate TGFbeta autocrine inhibitory activity and that dysfunction of these interactions contributes to malignant progression. During the past cycle of the project the applicant has found that both mutational inactivation of TGFbeta receptors as well as their repression by transcriptional inactivation provide mechanisms for loss of autocrine TGFbeta and malignant progression and that autocrine TGFbeta controlled steady state integrin and ECM levels. Cells with transcriptionally inactivated TGFbeta receptors were utilized to show that alpha5 integrin expression along with ligation to fibronectin led to expression of TGFbeta receptors, acquisition of autocrine TGFbeta activity and reversal of malignancy. Moreover, blockade of alpha5beta1 ligation resulted in stimulation of DNA synthesis and the reversal of TGFbeta1 inhibitory effects. Thus the applicant is now poised to determine how TGFbeta's and integrins converge in their control of DNA synthesis and proliferation. The renewal project focuses on two issues. The first is the mechanism by which alpha5beta1 ligation to FN stimulates TGFbeta receptor expression while the second issue is the mechanism by which disruption of alpha5beta1 ligation leads to stimulation of DNA synthesis. The applicant hypothesizes that integrin mediated signalling is responsible for TGFbeta receptor induction and that ligation of alpha5beta1 to FN facilitates TGFbeta inhibitory effects of the cell cycle.
Specific aims i nclude determination of the (1) structural regions of FN which contribute to control of TGFbeta receptor expression, (2) mechanism by which alpha5beta1 mediates TGFbeta receptor induction and (3) mechanism by which disruption of alpha5beta1 ligation leads to increased DNA synthesis and blockade of TGFbeta inhibition.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA050457-12
Application #
6328913
Study Section
Special Emphasis Panel (ZRG2-ET-2 (03))
Program Officer
Ault, Grace S
Project Start
1989-12-01
Project End
2002-11-30
Budget Start
2001-01-15
Budget End
2002-11-30
Support Year
12
Fiscal Year
2001
Total Cost
$237,718
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Surgery
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Sawhney, Rajinder S; Liu, Wensheng; Brattain, Michael G (2009) A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 219:152-61
Sawhney, Rajinder S; Cookson, Michelle M; Omar, Yasin et al. (2006) Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem 281:8497-510
Wang, Jing; Sergina, Natalia; Ko, Tien C et al. (2004) Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity. J Biol Chem 279:40237-44
Sawhney, Rajinder S; Cookson, Michelle M; Sharma, Bhavya et al. (2004) Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells. J Biol Chem 279:47379-90
Ammanamanchi, Sudhakar; Tillekeratne, Manoranjani P M; Ko, Tien C et al. (2004) Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells. Cancer Res 64:2509-15
Ammanamanchi, Sudhakar; Freeman, James W; Brattain, Michael G (2003) Acetylated sp3 is a transcriptional activator. J Biol Chem 278:35775-80
Gong, JianGen; Ammanamanchi, Sudhakar; Ko, Tien C et al. (2003) Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res 63:3340-6
Bandyopadhyay, Abhik; Zhu, Yong; Malik, Shazli N et al. (2002) Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21:3541-51
Sawhney, Rajinder S; Zhou, Guo-Hao K; Humphrey, Lisa E et al. (2002) Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. J Biol Chem 277:75-86
Yang, L; Yang, J; Venkateswarlu, S et al. (2001) Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol 188:383-93

Showing the most recent 10 out of 37 publications